SHL Telemedicine Ltd. (SMDCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SHL Telemedicine Ltd. (SMDCF) trades at $17.15. SHL Telemedicine Ltd. develops and markets personal telemedicine solutions, primarily focusing on remote cardiac monitoring. Market cap: $280.87M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for SMDCF: SMDCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SMDCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SMDCF: 1/1 perspectives are bearish.
SHL Telemedicine Ltd. (SMDCF) Healthcare & Pipeline Overview
SHL Telemedicine Ltd. provides remote cardiac monitoring solutions and telemedicine services, distinguishing itself through its SmartHeart mobile ECG device and collaborations with Mayo Clinic and Hebrew University. Operating in the healthcare information services sector, the company serves a global market with a focus on early heart attack detection.
What Is the Investment Thesis for SMDCF?
SHL Telemedicine Ltd. presents a focused investment opportunity within the growing telemedicine market. The company's strength lies in its specialized cardiac monitoring solutions, particularly the SmartHeart device, which offers a competitive advantage in early heart attack detection. A key value driver is the increasing adoption of remote patient monitoring, fueled by aging populations and the rising prevalence of cardiovascular diseases. The collaborations with Mayo Clinic and the Hebrew University of Jerusalem to develop AI-driven predictive tools for cardiac events could enhance the company's technological edge. However, the company's negative profit margin of -49.5% and a high P/E ratio of -1.20 indicate financial challenges that need to be addressed. Successful expansion into new geographic markets and strategic partnerships could drive revenue growth. Investors should monitor the company's ability to improve profitability and manage its operating expenses.
Based on FMP financials and quantitative analysis
SMDCF Key Highlights
- Market capitalization of $0.28 billion reflects its position as a smaller player in the telemedicine market.
- Gross margin of 45.4% indicates a reasonable ability to control the direct costs associated with its products and services.
- Negative profit margin of -49.5% signals significant challenges in achieving profitability.
- Beta of 0.53 suggests lower volatility compared to the overall market.
- Collaboration with Mayo Clinic to evaluate the impact of SmartHeart on post-heart attack outcomes.
Who Are SMDCF's Competitors?
Who Are SMDCF's Competitors?
SMDCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BTMD biote Corp. | $2.00 | -1.35% | $88.22M | 47 |
| HNGE Hinge Health, Inc. | $54.50 | +1.15% | 5B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.00 | +0.00% | $20.00M | 67 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FOXO FOXO Technologies Inc. | $0.00 | +0.00% | 3K | 63 |
| DOCS Doximity, Inc. | $21.40 | +1.57% | $4.00B | 52 |
| GEHC GE HealthCare Technologies Inc. | $64.67 | -3.05% | $29.42B | 52 |
| DH Definitive Healthcare Corp. | $0.91 | +3.36% | 96M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SMDCF's Key Strengths?
- Specialized expertise in cardiac monitoring.
- Proprietary SmartHeart ECG device.
- Established presence in Israel and Europe.
- Collaborations with Mayo Clinic and Hebrew University.
What Are SMDCF's Weaknesses?
- Negative profit margin.
- Limited geographic reach compared to larger competitors.
- Reliance on a relatively small number of products.
- High P/E ratio indicating potential overvaluation.
What Could Drive SMDCF Stock Higher?
- Results from the Mayo Clinic collaboration evaluating SmartHeart's impact on post-heart attack outcomes are expected in late 2026.
- Increasing adoption of remote patient monitoring solutions driven by aging populations.
- Expansion of telemedicine services in Europe and potential entry into new markets.
What Are the Key Risks for SMDCF?
- Intense competition in the telemedicine market could erode market share.
- Regulatory changes impacting telemedicine services could negatively affect operations.
- Negative profit margin and high P/E ratio raise concerns about financial sustainability.
- Technological obsolescence could render existing products less competitive.
What Are the Growth Opportunities for SMDCF?
- Expansion into new geographic markets: SHL Telemedicine has the opportunity to expand its presence beyond its current markets in Israel and Europe. Entering new regions, particularly in Asia and North America, could significantly increase its customer base and revenue streams. This expansion could be achieved through strategic partnerships with local healthcare providers and distributors. The global telemedicine market is expected to continue its strong growth trajectory, offering a favorable environment for SHL Telemedicine's geographic expansion.
- Increased adoption of remote patient monitoring: The trend towards remote patient monitoring is accelerating, driven by the need to reduce healthcare costs and improve patient outcomes. SHL Telemedicine is well-positioned to capitalize on this trend with its suite of remote monitoring devices. By targeting specific patient populations, such as those with chronic heart conditions, the company can drive adoption of its solutions and generate recurring revenue streams. The remote patient monitoring market is projected to experience double-digit growth in the coming years.
- Development of AI-powered predictive tools: SHL Telemedicine's collaboration with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop AI-powered predictive tools for cardiac events represents a significant growth opportunity. These tools could enhance the company's ability to provide proactive and personalized care, differentiating it from competitors. Successful development and commercialization of these tools could attract new customers and increase the value of its existing services. The AI in healthcare market is rapidly evolving, offering significant potential for innovation and growth.
- Strategic partnerships with health insurance companies: Partnering with health insurance companies can provide SHL Telemedicine with access to a large pool of potential customers. By integrating its solutions into insurance plans, the company can drive adoption and generate recurring revenue. These partnerships can also help to reduce the cost of healthcare by enabling early detection and prevention of cardiac events. Health insurance companies are increasingly looking to telemedicine solutions to improve patient outcomes and manage costs.
- Integration with wearable devices and mobile health platforms: Integrating SHL Telemedicine's solutions with wearable devices and mobile health platforms can enhance the user experience and expand its reach. This integration can enable seamless data collection and transmission, providing healthcare providers with real-time insights into patient health. By partnering with leading wearable device manufacturers and mobile health platform providers, the company can tap into a large and growing market. The wearable medical device market is experiencing rapid growth, driven by increasing consumer awareness and technological advancements.
What Opportunities Does SMDCF Have?
- Expansion into new geographic markets.
- Increased adoption of remote patient monitoring.
- Development of AI-powered predictive tools.
- Strategic partnerships with health insurance companies.
What Threats Does SMDCF Face?
- Intense competition in the telemedicine market.
- Regulatory changes affecting telemedicine services.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are SMDCF's Competitive Advantages?
- Specialized expertise in cardiac monitoring solutions.
- Proprietary technology, including the SmartHeart mobile ECG device.
- Established relationships with healthcare providers and insurance companies.
- Collaborations with leading medical institutions like Mayo Clinic and Hebrew University.
- First-mover advantage in certain geographic markets.
What Does SMDCF Do?
Founded in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. has evolved into a provider of personal telemedicine solutions across Israel, Europe, and internationally. The company's core business revolves around developing and marketing devices and services that enable remote patient monitoring, particularly in the area of cardiac health. Its flagship product, SmartHeart, is a personal mobile 12-lead ECG device designed for the early detection of heart attacks. Other products include CardioSen'C, Cardio'B, and Cardio Beeper 12/12, each offering varying levels of ECG monitoring and data transmission capabilities. Beyond cardiac monitoring, SHL Telemedicine offers a suite of remote monitoring devices, including TeleWeight for weight management, TelePress for blood pressure monitoring, TeleBreather for lung function assessment, and TelePulse Oximeter for measuring blood oxygen saturation and pulse rate. These devices transmit data to the company's telemedicine centers, where healthcare professionals can analyze the information and provide timely interventions. SHL Telemedicine serves a diverse clientele, including individual patients, health insurance companies, hospitals, clinics, physicians, and other healthcare providers. The company leverages telephonic and internet communication technology to deliver its services, emphasizing accessibility and convenience for its users. SHL Telemedicine has strategic collaborations with Mayo Clinic and the Hebrew University of Jerusalem, focusing on improving cardiac care through technology and AI.
What Products and Services Does SMDCF Offer?
- Develops and markets personal mobile 12-lead ECG devices for detecting heart attacks.
- Offers remote blood pressure and weight monitoring devices for personal use.
- Provides electronic handheld devices for lung function and blood oxygen saturation testing.
- Operates telemedicine centers for analyzing medical data transmitted from monitoring devices.
- Serves patients, health insurance companies, hospitals, and clinics.
- Utilizes telephonic and internet communication technology for delivering telemedicine services.
- Collaborates with Mayo Clinic and Hebrew University on cardiac care technology and AI.
How Does SMDCF Make Money?
- Sells personal telemedicine devices, such as the SmartHeart ECG device.
- Provides subscription-based telemedicine services to patients and healthcare providers.
- Partners with health insurance companies to offer remote monitoring solutions to their members.
- Generates revenue from data analysis and reporting services for healthcare providers.
What Industry Does SMDCF Operate In?
SHL Telemedicine operates within the rapidly expanding telemedicine market, driven by factors such as an aging global population, increasing prevalence of chronic diseases, and advancements in communication technology. The industry is characterized by intense competition, with players ranging from large healthcare providers offering telemedicine services to specialized companies like SHL Telemedicine focusing on niche areas such as cardiac monitoring. The global telemedicine market is projected to reach hundreds of billions of dollars in the coming years, presenting significant growth opportunities for companies that can effectively differentiate themselves and capture market share.
Who Are SMDCF's Key Customers?
- Individual patients seeking remote cardiac monitoring.
- Health insurance companies looking to improve patient outcomes and manage costs.
- Hospitals and clinics using telemedicine solutions for remote patient care.
- Physicians and other healthcare providers seeking to enhance their services with remote monitoring capabilities.
SMDCF Financials
SMDCF Latest News
No recent news available for SMDCF.
SMDCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SMDCF.
Price Targets
Wall Street price target analysis for SMDCF.
SMDCF MoonshotScore
What does this score mean?
The MoonshotScore rates SMDCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Erez Nachtomy
CEO
Erez Nachtomy serves as the CEO of SHL Telemedicine Ltd. His background includes extensive experience in managing technology-driven healthcare companies. He has a proven track record in strategic planning, business development, and operational execution. Prior to joining SHL Telemedicine, Nachtomy held leadership positions in various healthcare and technology firms, where he focused on driving innovation and growth. His expertise spans across telemedicine, medical devices, and healthcare IT.
Track Record: Under Erez Nachtomy's leadership, SHL Telemedicine has focused on expanding its remote patient monitoring solutions and strengthening its strategic partnerships. He has overseen the company's collaborations with Mayo Clinic and the Hebrew University of Jerusalem, aiming to enhance cardiac care through technology and AI. Nachtomy has also been instrumental in driving the company's international expansion efforts.
SMDCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that SHL Telemedicine Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can increase the risk for investors, as it may be difficult to obtain reliable information about the company's financial performance and operations. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for price manipulation due to low trading volumes.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited access to company information and financial reports.
- Greater price volatility and wider bid-ask spreads.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any red flags.
- The company has been in operation since 1987.
- SHL Telemedicine has established partnerships with reputable medical institutions like Mayo Clinic and Hebrew University.
- The company offers FDA-approved medical devices, such as the SmartHeart ECG device.
- SHL Telemedicine serves a diverse customer base, including patients, healthcare providers, and insurance companies.
SHL Telemedicine Ltd. Healthcare Stock: Key Questions Answered
What does SHL Telemedicine Ltd. do?
SHL Telemedicine Ltd. develops and markets personal telemedicine solutions, primarily focusing on remote cardiac monitoring. The company's flagship product, SmartHeart, is a mobile 12-lead ECG device designed for early heart attack detection. In addition to cardiac monitoring, SHL Telemedicine offers a range of remote monitoring devices for weight management, blood pressure, lung function, and blood oxygen saturation. The company serves patients, healthcare providers, and insurance companies, leveraging telephonic and internet communication technology to deliver its services.
What do analysts say about SMDCF stock?
AI analysis is pending for SMDCF. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, gross margin, profit margin, and P/E ratio. Growth considerations include the company's ability to expand into new markets, develop innovative products, and form strategic partnerships.
What are the main risks for SMDCF?
The main risks for SHL Telemedicine Ltd. include intense competition in the telemedicine market, regulatory changes impacting telemedicine services, and potential technological obsolescence. The company's negative profit margin and high P/E ratio also raise concerns about its financial sustainability. As an OTC stock, SMDCF is subject to additional risks, including limited regulatory oversight, potential for price manipulation, and greater price volatility. Investors should carefully consider these risks before investing in SMDCF.
What are the key factors to evaluate for SMDCF?
Evaluating SMDCF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Specialized expertise in cardiac monitoring. Primary risk to monitor: Intense competition in the telemedicine market could erode market share. This is not financial advice.
How frequently does SMDCF data refresh on this page?
SMDCF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SMDCF's recent stock price performance?
Recent price movement in SHL Telemedicine Ltd. (SMDCF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in cardiac monitoring. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SMDCF overvalued or undervalued right now?
Determining whether SHL Telemedicine Ltd. (SMDCF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SMDCF?
Before investing in SHL Telemedicine Ltd. (SMDCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights.